Verenium Corporation Management Discusses Q4 2010 Results - Earnings Call Transcript
I'd now like to take a few minutes to discuss two topics. First, I will describe Verenium’s strategy and how we approach the opportunities we see to acquire technology. And then I will describe the vision we have for 2011.
Simply put, our strategy is to use our enzyme technologies to develop and sell products that improve the performance of industrial processes. Our vision is to build a high growth, highly profitable industrial biotech business by capturing a portion of the value our products create.
Part of our growth will come from further penetrating our existing target markets with our current nine commercial products as well as new products from our pipeline and part will come from launching products for markets we don't currently serve.
We believe the near term growth available through these two actions is significant relative to our business today. And while we also see broader areas and large markets where our platform technology has direct application such as metabolic engineering, our job today is to maintain our focus so we convert the large opportunities we see in our product lines and product pipeline into revenue and profit growth.In the near term, we will demonstrate progress towards this vision most tangibly by growing our current product revenue, improving the efficiency of our manufacturing base, controlling costs and announcing partnerships for future areas of focus. We believe 2011 will be a transformational year for most if not all, on most and not all of these fronts. I would like to bring the high level strategy into a more action oriented set of steps to explain exactly how we execute on our business plan. Our decision to invest in any opportunity requires a complete plan which addresses the critical elements that influence our success, which I will summarize as markets, products and channel. I will walk through each of these using our animal health and nutrition product line as an example. Read the rest of this transcript for free on seekingalpha.com
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV